Edition:
United States

SCYNEXIS Inc (SCYX.OQ)

SCYX.OQ on NASDAQ Stock Exchange Global Market

0.53USD
3:59pm EST
Change (% chg)

$-0.05 (-8.33%)
Prev Close
$0.58
Open
$0.59
Day's High
$0.61
Day's Low
$0.52
Volume
129,025
Avg. Vol
38,991
52-wk High
$2.44
52-wk Low
$0.52

Latest Key Developments (Source: Significant Developments)

Scynexis Announces FDA Agreement With Company-Proposed Phase 3 Vulvovaginal Candidiasis Program For Oral Ibrexafungerp
Tuesday, 23 Oct 2018 09:00am EDT 

Oct 23 (Reuters) - SCYNEXIS Inc ::SCYNEXIS ANNOUNCES FDA AGREEMENT WITH COMPANY-PROPOSED PHASE 3 VULVOVAGINAL CANDIDIASIS PROGRAM FOR ORAL IBREXAFUNGERP.SCYNEXIS INC - ON TARGET TO INITIATE PHASE 3 REGISTRATION PROGRAM IN Q4 OF 2018.SCYNEXIS INC - PLAN TO FILE A NEW DRUG APPLICATION (NDA) FOR TREATMENT OF VVC IN 2020.  Full Article

Scynexis Provides Corporate And SCY-078 Pipeline Update
Thursday, 4 Jan 2018 04:05pm EST 

Jan 4 (Reuters) - Scynexis Inc ::SCYNEXIS PROVIDES CORPORATE AND SCY-078 PIPELINE UPDATE.SCYNEXIS INC - ‍INTENDS TO INITIATE A PHASE 1 STUDY IN HEALTHY VOLUNTEERS IN Q3 2018, PENDING FDA'S REVIEW FOR LIPOSOMAL IV FORMULATION OF SCY-078​.SCYNEXIS INC - ‍PLANS TO INITIATE A PHASE 2B STUDY OF SCY-078 IN INVASIVE CANDIDIASIS WITH LIPOSOMAL IV FORMULATION IN Q4 OF 2018​.SCYNEXIS - ‍ANTICIPATES DOSE REGIMEN SELECTED FROM DOVE STUDY TO BE SUBSEQUENTLY EVALUATED IN PHASE 3 STUDIES FOLLOWING END-OF-PHASE 2 MEETING WITH FDA​.  Full Article

Scynexis reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 04:20pm EST 

Nov 7 (Reuters) - Scynexis Inc :Scynexis reports third quarter 2017 financial results and provides company update.Q3 loss per share $0.31.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.  Full Article